{"id":"niridazole","rwe":[{"pmid":"41188050","year":"2025","title":"Multidisciplinary Preclinical Investigations on Ferrocenyl, Ruthenocenyl, and Benzyl Derivatives of Niridazole as New Drug Candidates against Schistosomiasis.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"},{"pmid":"34415904","year":"2021","title":"The efficacy of topical, oral and surgical interventions for the treatment of tungiasis: A systematic review of the literature.","finding":"","journal":"PLoS neglected tropical diseases","studyType":"Clinical Study"},{"pmid":"34237261","year":"2021","title":"Clinical interventions for tungiasis (sand flea disease): a systematic review.","finding":"","journal":"The Lancet. Infectious diseases","studyType":"Clinical Study"},{"pmid":"29256130","year":"2017","title":"Antimicrobials and Male Reproduction.","finding":"","journal":"Advances in experimental medicine and biology","studyType":"Clinical Study"},{"pmid":"20627145","year":"2010","title":"Research and development of antischistosomal drugs in the People's Republic of China a 60-year review.","finding":"","journal":"Advances in parasitology","studyType":"Clinical Study"}],"tags":[{"label":"niridazole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"P02BX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Amebicides","category":"pharmacology"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiplatyhelmintic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Schistosomicides","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nitrothiazol","offLabel":[],"synonyms":["niridazole","nitrothiamidazol","nitrothiamidazole","nitrothiazol","nitrothiazole"],"timeline":[],"approvals":[],"brandName":"Nitrothiazol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"niridazole","explanation":"Imagine Niridazole as a disruptor of the parasite's internal machinery. By blocking key enzymes, it prevents the parasite from producing the energy it needs to survive, ultimately killing it. This targeted approach helps minimize harm to the host while effectively treating the infection.","oneSentence":"Niridazole works by interfering with the metabolic processes of certain parasites, ultimately leading to their death.","technicalDetail":"Niridazole is thought to exert its effects by inhibiting the parasite's pyruvate ferredoxin oxidoreductase (PFOR) enzyme, which is essential for energy production in these organisms."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1941","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIRIDAZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:40:29.432460","biosimilars":[],"competitors":[{"drugName":"triclabendazole","drugSlug":"triclabendazole","fdaApproval":"2019-02-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"niridazole","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"triclabendazole","brandName":"triclabendazole","genericName":"triclabendazole","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006108","UNII":"N116U8Y5QQ","CHEBI":"CHEBI:82349","INN_ID":"2234","UMLSCUI":"C0028113","ChEMBL_ID":"CHEMBL152632","KEGG_DRUG":"D05170","DRUGBANK_ID":"DB13661","PUBCHEM_CID":"6093","SNOMEDCT_US":"55944008","MESH_DESCRIPTOR_UI":"D009560"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":353,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"P02BX02","allCodes":["P02BX02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 28","pmid":"41188050","title":"Multidisciplinary Preclinical Investigations on Ferrocenyl, Ruthenocenyl, and Benzyl Derivatives of Niridazole as New Drug Candidates against Schistosomiasis.","journal":"ChemMedChem"},{"date":"2021 Aug","pmid":"34415904","title":"The efficacy of topical, oral and surgical interventions for the treatment of tungiasis: A systematic review of the literature.","journal":"PLoS neglected tropical diseases"},{"date":"2021 Aug","pmid":"34237261","title":"Clinical interventions for tungiasis (sand flea disease): a systematic review.","journal":"The Lancet. Infectious diseases"},{"date":"2017","pmid":"29256130","title":"Antimicrobials and Male Reproduction.","journal":"Advances in experimental medicine and biology"},{"date":"2010","pmid":"20627145","title":"Research and development of antischistosomal drugs in the People's Republic of China a 60-year review.","journal":"Advances in parasitology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nitrothiazol, also known as Niridazole, is a small molecule drug in the niridazole class. Its exact target is unknown, but it is used to treat certain parasitic infections. The commercial status of Niridazole is unclear, and it may be patented or available as a generic medication. Key safety considerations are not well-documented. Niridazole's mechanism of action and pharmacokinetic properties are also not well-established.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}